For example, in Checkmate 227 study, nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) achieved durable clinical benefit in all patients regardless of tumor PD-L1 expression [8]. This evidence concerns the gene CTLA4 and neoplasm.